We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Repair of Denucleated Intervertebral Discs

By HospiMedica staff writers
Posted on 04 Jul 2001
A biomechanical study has shown that the application of a protein hydrogel can restore a denucleated interdiscal void to normal height and compressibility, restoring normal spine function and potentially eliminating lower back pain. More...
The results were presented at the 14th Annual Meeting of the International Intradiscal Therapy Society in Phoenix (AZ, USA).

Denucleation of intervertebral discs is a common treatment for lower back pain that involves the surgical removal of damaged or diseased disc materials, resulting in motion destabilization and progressive reduction in disc height. A device called BioDisc containing a protein hydrogel is injected in fluid form into the denucleated disc space and serves as a pliable support solid to restore disc height and stability while preserving motion. BioDisc employs a minimally invasive delivery system incorporating a dual-chamber applicator that allows a surgeon to inject the biomaterial into the void created by the removal of disc materials.

BioDisc was developed by CryoLife, Inc. (Kennesaw, GA, USA). Phase I of the biomechanical study concluded that the application of the technology will produce the desired results. Phase II animal studies are currently under way and are expected to be completed in the fall. "The commercial introduction of BioDisc would represent a major advancement in spinal disc surgical technology and offer orthopedic surgeons and their patients a more efficient and cost-effective alternative to current disc repair methods,” said Steven G. Anderson, president and CEO of CryoLife.




Related Links:
CryoLife

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.